120 related articles for article (PubMed ID: 7504125)
21. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
23. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
[TBL] [Abstract][Full Text] [Related]
24. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
25. [Comparative in vitro study of anticoagulant activity of RA36 DNA aptamer in human, rabbit, and rat blood plasma].
Savchik EIu; Kalinina TB; Drozd NN; Makarov VA; Zav'ialova EG; Lapsheva EN; Babiĭ AV; Mudrik NN; Pavlova GV; Golovin AV; Kopylov AM
Eksp Klin Farmakol; 2012; 75(11):13-8. PubMed ID: 23323327
[TBL] [Abstract][Full Text] [Related]
26. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat.
Butler KD; Dolan SL; Talbot MD; Wallis RB
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):459-64. PubMed ID: 8329573
[TBL] [Abstract][Full Text] [Related]
27. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
Esslinger HU; Köhne S; Radziwon P; Walenga JM; Breddin HK
Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328
[TBL] [Abstract][Full Text] [Related]
28. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
29. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.
Gaussem P; Dubar M; le Bonniec B; Richard-Lordereau I; Jochemsen R; Aiach M
Br J Clin Pharmacol; 2002 Feb; 53(2):147-54. PubMed ID: 11851638
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
Bichler J; Siebeck M; Fichtl B; Fritz H
Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
[TBL] [Abstract][Full Text] [Related]
31. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
32. The pharmacological modulation of thrombin-induced cerebral thromboembolism in the rabbit.
May GR; Paul W; Crook P; Butler KD; Page CP
Br J Pharmacol; 1992 May; 106(1):133-8. PubMed ID: 1504722
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
34. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Beiderlinden M; Werner P; Bahlmann A; Kemper J; Brezina T; Schäfer M; Görlinger K; Seidel H; Kienbaum P; Treschan TA
BMC Anesthesiol; 2018 Feb; 18(1):18. PubMed ID: 29426286
[TBL] [Abstract][Full Text] [Related]
36. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
38. [Profibrinolytic activity of recombinant hirudin?].
Tsakiris DA; Meyer D; Fabbri J; Close P; Marbet GA
Schweiz Med Wochenschr; 1991 Mar; 121(10):338-40. PubMed ID: 2028237
[TBL] [Abstract][Full Text] [Related]
39. Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Ji X; Meng R; Zhou J; Ling F; Jia J
Neurol Res; 2006 Jan; 28(1):46-9. PubMed ID: 16464362
[TBL] [Abstract][Full Text] [Related]
40. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Topol EJ; Bonan R; Jewitt D; Sigwart U; Kakkar VV; Rothman M; de Bono D; Ferguson J; Willerson JT; Strony J
Circulation; 1993 May; 87(5):1622-9. PubMed ID: 8491018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]